4.6 Review

Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications

Journal

JOURNAL OF NEUROSURGERY
Volume 133, Issue 3, Pages 655-663

Publisher

AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/2019.5.JNS19364

Keywords

experimental therapeutics; glioblastoma; GBM; glioma stem cells; GSC; intratumoral heterogeneity; oncology

Funding

  1. NIH/National Cancer Institute [P01 CA163205, R21 CA175875]
  2. NIH/National Institute of Neurological Disorders and Stroke [R01 NS083767, R01 NS087913]
  3. University of Alabama Medical Scientist Training Program

Ask authors/readers for more resources

Glioblastoma (GBM), the most common primary malignant brain tumor in adults, is associated with significant morbidity and mortality despite maximal safe resection followed by chemo- and radiotherapy. GBMs contain self-renewing, tumorigenic glioma stem cells that contribute to tumor initiation, heterogeneity, therapeutic resistance, and recurrence. Intratumoral heterogeneity (ITH) of GBMs is also a major contributing factor to poor clinical outcomes associated with these high-grade glial tumors. Herein, the authors summarize recent discoveries and advances in the molecular and phenotypic characterization of GBMs with particular focus on ITH. In so doing, they attempt to highlight recent advances in molecular signatures/properties and metabolic alterations in an effort to clarify translational implications that may ultimately improve clinical outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available